ACHV Share Price Performance
US$2.64
-1.87 (-41.46%)
Price US$2.64
Share PriceUS$2.64
ACHV Community Narratives
There are no narratives available yet.
Recent ACHV News & Updates
No updates
Achieve Life Sciences, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.93
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 95.8%
Achieve Life Sciences, Inc. Competitors
About ACHV
- Founded
- n/a
- Employees
- 25
- CEO
- WebsiteView website
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
U.S. Market Performance
- 7 Days: 0.2%
- 3 Months: 12.2%
- 1 Year: 19.9%
- Year to Date: 7.6%
The Consumer Staples sector gained 3.2% while the market remained flat over the last week. As for the longer term, the market has risen 20% in the past 12 months. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading